Garo H. Armen, executive chair and principal officer of Protagenic Therapeutics Inc. (NASDAQ: PTIX), acquired 20,000 shares of common stock on August 21, 2026, at $0.65 per share, totaling $13,000. The transaction follows a 122% surge in the company’s stock over the prior week, which reached $1.10 according to InvestingPro data.
The purchase reflects a direct increase in Armen’s holdings, bringing his total direct ownership to 73,533 shares. The stock’s recent performance has outpaced InvestingPro’s fair value estimate, as noted in a data tip accompanying the transaction report.
Protagenic Therapeutics, a biopharmaceutical company, continues to see heightened investor interest amid the sharp price movement.
